Compare Amgen, Inc. (AMGN) vs Twilio Inc (TWLO) Price & Performance

Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.

Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.

Twilio (TWLO) trades at $250.06, up 3.64% with strong technical momentum and bullish moving average signals. The stock has delivered three consecutive earnings beats, with Q2 2026 EPS of $1.47 beating expectations by 11%. Revenue growth accelerated to 22% year-over-year in Q2, prompting management to raise full-year guidance to 18-18.5% growth. The company achieved record free cash flow generation with margins improving significantly.

Twilio presents compelling growth prospects with accelerating revenue and robust cash flow generation. However, elevated valuation multiples (P/E 35.35, EV/EBITDA 75.54) and overbought technical indicators suggest near-term consolidation risk. Analyst consensus remains strongly bullish with 77% buy ratings and $266.31 price target, representing 6.5% upside from current levels.